Vaccine company Eurocine Vaccines AB reported on Thursday the completion of dosing this week under its planned second clinical study of its quadrivalent influenza vaccine candidate, Immunose FLU.
The company said the Immunose FLU was developed with the aim to become a modern and effective nasal influenza vaccine.
According to CSO Dr Anna-Karin Maltais, the company has chosen the broader quadrivalent, rather than trivalent, vaccine for its product candidate following this year's severe influenza outburst.
Additionally, the elderly always suffer most from influenza disease and Immunose FLU can offer a better and more convenient vaccine in this segment. It also plans to offer the first nasal influenza vaccine for children younger than two years, adds Hans Arwidsson, CEO of Eurocine Vaccines.
In conjunction, the strategy behind this present study and its design was presented in February 2018. The results are expected in second half of 2018, concluded the company.
FLX Bio Inks Clinical Trial Collaboration Agreement with Merck for Ongoing Phase 1/2 Study of FLX475
Nouscom appoints John F McDonald as independent director to its board of directors
Sanofi awarded US FDA priority review for dengue vaccine candidate
DelSiTech Ltd awarded funding by Bill & Melinda Gates Foundation
Seqirus passes US FDA approval for AFLURIA QUADRIVALENT (Influenza Vaccine) in the US
AIVITA Biomedical wins PMDA approval in Japan for ROOT OF CANCER Technology